Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 11 of 26 · 1223 articles
Cure8 found this source from marketwatch.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
Thiopurines are commonly used in IBD (azathioprine, 6-mercaptopurine). This review links these drugs — especially 6-thioguanine — to liver microvascular injury that can lead to portal hypertension, which may present...
The study reports a newly discovered class of marine-derived meroterpenoids and identifies a lead compound that reduced inflammatory markers and improved colitis in mice, which could eventually inform new drug...
For people with UC on long-term tofacitinib, this trial provides evidence about the chances of keeping remission after stepping down dose and about safety differences between 10 mg and 5 mg twice daily over 30 months.
Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.
Clostridium difficile infection is an important and potentially serious complication in ulcerative colitis. A blood‑marker–based risk model could help identify higher‑risk patients noninvasively so clinicians can...
This study reports a new engineered platform that can catalytically degrade TNF‑α, the same inflammatory cytokine targeted by several IBD therapies. If translated to humans, it could offer longer‑lasting mucosal...
A systematic review finds risankizumab (an IL-23 inhibitor) effective and generally well tolerated for moderate-to-severe Crohn's disease and ulcerative colitis, including in patients who failed prior biologics. This...
Corticosteroid use during IBD treatment periods was associated with higher rates of serious infections across drug classes and age groups, which may affect decisions about steroid use and infection-prevention planning.
The review aggregates published instances where combining two advanced immunomodulators was followed by improvement in pyoderma gangrenosum, a serious skin complication often seen in people with IBD. However, the...
People with IBD increasingly also have obesity and type 2 diabetes; this commentary suggests GLP-1 receptor agonists might affect not only metabolism but also inflammation and clinical outcomes relevant to IBD, which...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
If you’re stable on ustekinumab for Crohn’s disease, this multicenter study found that switching to an approved biosimilar produced similar 6-month remission and safety outcomes to staying on the original product. That...
PG is often linked with IBD and other systemic conditions, so approaches that treat the underlying comorbidity can improve ulcer healing and lower relapse risk. Patients with IBD who develop PG may benefit from therapies...
The review connects UC pathological features to specific drug-delivery design needs, which could guide development of therapies that reach and act effectively in inflamed colon tissue. For people with UC, better-targeted...
Cure8 could only read part of this source from The American Journal of Gastroenterology, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...
This study tests a common clinical question: whether increasing vedolizumab frequency helps patients who show no endoscopic response after 6 months. The results suggest intensification raised drug levels but did not...
This registry will track long-term safety and clinical outcomes in children with IBD, with a focus on infliximab (an anti‑TNF biologic) versus non‑biologic therapies. Long follow-up could help identify uncommon or late...
Phase 3 testing of guselkumab (an IL-23–targeting biologic) in moderately to severely active ulcerative colitis could expand treatment options if the trial meets its endpoints and shows an acceptable safety profile. The...
This case shows that upadacitinib, a JAK inhibitor used for refractory IBD, can cause severe anemia in rare cases but that dose reduction (rather than permanent discontinuation) may reversibly restore blood counts while...
Butyrate supports intestinal health and is often low in IBD. A single oral compound that reliably restores luminal butyrate could — if proven safe and effective in humans — offer a new way to treat ulcerative colitis or...
A new subcutaneous induction option for risankizumab could make starting this biologic easier for many adults with moderate-to-severe Crohn's disease by avoiding infusions, potentially increasing access and convenience.
Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...
Researchers and clinicians are exploring fungi’s role in IBD beyond bacteria. For patients, seeing Candida in stool tests is usually a signal of microbiome disruption rather than proof of fungal infection that requires...
People with IBD and other immune conditions may develop weaker or lower‑quality antibody responses after COVID‑19 vaccination compared with healthy people, and transplant recipients showed the largest impairments. That...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from tradingview.com.
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.
A subcutaneous induction option could make starting risankizumab easier and less burdensome than IV infusions for many people with Crohn's disease, potentially expanding access and convenience.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Risankizumab, and IL-23 inhibitor. The original article is from msn.com.
A new subcutaneous induction option for risankizumab could make starting IL‑23 therapy more convenient for adults with moderately to severely active Crohn’s disease and expand choices for those who have failed prior...
If approved, a subcutaneous induction option for risankizumab would let eligible adults start and continue treatment without needing an infusion visit, which can be more convenient and reduce infusion-related costs and...
This bill could make lower-cost biosimilars more available at the pharmacy counter, potentially reducing out-of-pocket costs and helping people with Crohn’s disease and other conditions stay on prescribed biologic...
News about large drugmakers’ pipelines and analyst optimism can affect future availability and development of therapies for IBD. Mentions of a drug (Tulisokibart) being developed for ulcerative colitis and Crohn’s may...
Patients, clinicians, and payers may care because the analysis addresses the relative economic value of two approved biologic options (vedolizumab and risankizumab) for Crohn’s disease treatment in Italy and could...
This trial tests whether a seaweed-derived fucoidan given with standard 5-ASA therapy can change biomarkers linked to mucosal healing (fecal calprotectin, fecal short-chain fatty acids) and stool consistency in people...
Researchers and patients tracking new IBD therapies may care because this is the first human study of a GlaxoSmithKline investigational drug aimed at colitis/ulcerative colitis — an early step that could lead to future...
The FDA label clarifies that ZYMFENTRA (a TNF blocker) is indicated for maintenance treatment of moderate–severe Crohn’s disease and ulcerative colitis after prior infliximab, and it carries strong safety warnings...
Prednisone is commonly used short-term in IBD flares; an FDA label update clarifies approved uses and dosing considerations that affect how clinicians prescribe it and how patients should take and stop the drug.
Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...
If you or a patient is about to start infliximab for ulcerative colitis, routine blood counts may help identify those unlikely to respond to induction therapy; a high negative predictive value suggests these markers...
A JAK inhibitor (upadacitinib) used for moderate–severe ulcerative colitis can cause neutropenia; this case report discusses how it was identified and managed, which matters for patients on the drug and clinicians...
NUDT15 genotyping can identify people at high risk of severe thiopurine-induced myelosuppression; if cost-effective, testing could change how clinicians choose or dose thiopurines for IBD, potentially preventing serious...
Researchers used laboratory mouse and cell models to show that total glucosides of paeony (TGP) may reduce inflammation linked to ulcerative colitis and identified molecular pathways (COX‑2/arachidonic acid, NF‑κB, MAPK,...
TL1A-DR3 is implicated in both inflammation and fibrosis in IBD, so targeting it could address active disease and reduce fibrotic complications that lead to strictures. New TL1A-blocking antibodies are already in...
The study links a polyphenol-rich diet to a specific microbiome change and a microbial metabolite (4-HPAA) that reduced inflammation in mouse models — offering a possible mechanism by which diet could influence Crohn's...
Delays in diagnosis and restricted access to therapies can allow Crohn’s inflammation to progress, increasing the chance of bowel damage and worse outcomes. Progress on earlier detection and better matching of treatments...
These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...
